ArticleJournal of clinical medicine2021
Extracellular Vesicles: An Important Biomarker in Recurrent Pregnancy Loss?
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.
- Extracellular vesicles in reproductive biology and disorders: a comprehensive review.Frontiers in endocrinology · 2025Pooled it
- Quantitative proteomic profiling of placental extracellular vesicles in recurrent pregnancy loss reveals their role in feto-maternal crosstalk.BMC pregnancy and childbirth · 2026Article
- [The role of extracellular vesicles in early embryo development and their application in assisted reproductive technologies].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Exploring the Vertical Transmission of Exosomes in Diagnostic and Therapeutic Targets for Pregnancy Complications.ACS biomaterials science & engineering · 2025Review
- A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Article
- Placenta Extracellular Vesicles: Messengers Connecting Maternal and Fetal Systems.Biomolecules · 2024Review
- A critical review of the recent concept of regulatory performance of DNA Methylations, and DNA methyltransferase enzymes alongside the induction of immune microenvironment elements in recurrent pregnancy loss.Toxicology reports · 2024Review
- Exosomal encapsulation of miR-3198 promotes proliferation and migration of trophoblasts in preeclampsia.Journal of assisted reproduction and genetics · 2024Article
- Extracellular vesicles from mouse trophoblast cells: Effects on neural progenitor cells and potential participants in the placenta-brain axis†.Biology of reproduction · 2024Article
- Extracellular vesicles as carriers of mRNA: Opportunities and challenges in diagnosis and treatment.Theranostics · 2024Review
- Circulating extracellular vesicles in healthy and pathological pregnancies: A scoping review of methodology, rigour and results.Journal of extracellular vesicles · 2023Article
- The Diagnostics and Treatment of Recurrent Pregnancy Loss.Journal of clinical medicine · 2023Review
- Increased levels of nerve growth factor accompany oxidative load in recurrent pregnancy loss. Machine learning applied to FT-Raman spectra study.Bioprocess and biosystems engineering · 2023Article
- HLA-G and Recurrent Pregnancy Loss.International journal of molecular sciences · 2023Review
- Exosomes: The role in mammalian reproductive regulation and pregnancy-related diseases.Frontiers in physiology · 2023Review
- Extracellular vesicles and immune response during pregnancy: A balancing act.Immunological reviews · 2022Review
- The implications of exosomes in pregnancy: emerging as new diagnostic markers and therapeutics targets.Cell communication and signaling : CCS · 2022Review
- Messenger roles of extracellular vesicles during fertilization of gametes, development and implantation: Recent advances.Frontiers in cell and developmental biology · 2022Review
- Special Issue Recurrent Pregnancy Loss: Etiology, Diagnosis, and Therapy.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent pregnancy loss (RPL) has an estimated incidence of 1-3% of all couples. The etiology is considered to be multifactorial. Extracellular vesicles (EVs) take part in numerous different physiological processes and their contents show the originating cell and pathophysiological states in different diseases. In pregnancy disorders, changes can be seen in the composition, bioactivity and concentration of placental and non-placental EVs. RPL patients have an increased risk of pregnancy complications. The aim of this prospective study was to examine whether measuring different specific EV markers in plasma before and during pregnancy could be used as predictors of pregnancy loss (PL) in women with RPL. Thirty-one RPL patients were included in this study; 25 had a live birth (LB group) and six had a new PL (PL group). Five blood samples were obtained, one before achieved pregnancy and the others in gestational week 6, 8, 10 and 16. Moreover, some of the patients received intravenous immunoglobulin (IVIG) infusions as part of treatment, and it was also examined whether this treatment influenced the EV levels. Seventeen EV markers specific for the immune system, coagulation, placenta and hypoxia were analyzed in the samples with EV Array, a method able to capture small EVs by using an antibody panel targeting membrane proteins. Comparing the LB and PL groups, one EV marker, CD9, showed a significant increase from before pregnancy to gestational week 6 in the PL group. The changes in the other 16 markers were nonsignificant. One case of late-onset PL showed steeply increasing levels, with sudden decrease after gestational week 10 in nine of 17 markers. Moreover, there was an overall increase of all 17 markers after IVIG treatment in the LB group, which was significant in 15 of the markers. Whether increases in EVs positive for CD9 characterize RPL patients who subsequently miscarry should be investigated in future larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.